

MNKD Products & Pipeline

■ Cardiometabolic
 ■ Orphan Lung

Product	Targeted Indications	Pre-IND	Phase 1	Phase 2	Phase 3	Approval
Afrezza® (insulin human) Inhalation Powder	T1DM / T2DM (adults)	Marketed				Marketed
	T1DM / T2DM (pediatrics)	PDUFA: Q2 2026				
V-Go® All-in-One Insulin Delivery Patch	T1DM / T2DM (adults)	Marketed				Marketed
FUROSCIX® (furosemide injection) <small>(marketed by scPharmaceuticals, a wholly owned subsidiary of MannKind)</small>	Edema from CHF / CKD	Marketed				Marketed
FUROSCIX ReadyFlow™ Autoinjector	Edema from CHF / CKD	PDUFA: Q3 2026				
Bumetanide DPI <small>(MNKD-701)</small>	Edema from CHF / CKD	Pre-Clinical				
Tyvaso DPI® (treprostinil) Inhalation Powder <small>(marketed by United Therapeutics)</small>	PAH / PH-ILD	Marketed				Marketed
Nintedanib DPI <small>(MNKD-201)</small>	IPF, PPF	Phase 2 (INFLO-2 study)				
Ralinepag DPI (MNKD-1501) <small>(collaboration with United Therapeutics)</small>	PAH, PH-ILD, IPF, PPF	Pre-Clinical				